Quality Assurance Associate
SAB
Quality Assurance Associate
SAB
Develops fully human polyclonal antibodies
SAB Biotherapeutics creates fully human polyclonal antibody therapies using its DiversitAb platform, which uses genetically engineered transchromosomic cattle to produce human antibodies without needing donors. The antibodies are designed to address immunology disorders and infectious diseases, with programs like SAB-142 for Type 1 Diabetes, SAB-176 for severe influenza, and SAB-195 for C. diff. The platform enables faster development, potentially moving from concept to clinic in under five months. Unlike traditional monoclonal antibodies, SAB uses polyclonal human antibodies and works with governments and pharma partners to advance its pipeline toward approval and commercialization.
Explore more opportunities at SAB